This document analyzes clinical trial data from 2016 to assess industry strategies and performance. It finds that oncology trials dominated with 826 completions, while type 2 diabetes had the most with 190. Novartis had the most overall industry-sponsored trials completed in 2016 at 165. The document also examines trial completion rates by disease, phase, and sponsor to evaluate relative trial success rates across different areas.
Experts from Informa’s Medtrack, Trialtrove and Strategic Transactions teams presented a panel discussion at the recent T3 Conference in Orlando, Florida.
Similar to humans, animals too suffer from chronic diseases. Arthritis and other orthopedic conditions, chronic kidney disease, cancer, hepatitis and other liver diseases, skin allergies, diabetes mellitus, inflammatory bowel disease, and thyroid disorders are among the common chronic diseases in pets.
Experts from Informa’s Medtrack, Trialtrove and Strategic Transactions teams presented a panel discussion at the recent T3 Conference in Orlando, Florida.
Similar to humans, animals too suffer from chronic diseases. Arthritis and other orthopedic conditions, chronic kidney disease, cancer, hepatitis and other liver diseases, skin allergies, diabetes mellitus, inflammatory bowel disease, and thyroid disorders are among the common chronic diseases in pets.
Your fast-pass to the news, insights, and storylines you need to know.
Watch the full webinar here http://ow.ly/4mOGmk
Hosted by Master of Ceremonies Ian Lloyd, senior director of Pharmaprojects and data integration, this webinar spotlights the blockbuster trends and rising stars of global R&D 2016 as seen in this year’s Annual Review.
During this presentation, Ian Lloyd & Scrip Managing Editor, Alex Shimmings cover:
>> Year-on-year growth
>> Clinical phases trends
>> Top companies and the shape of the industry
>> Mergers and acquisitions
>> Trending therapies, diseases, drug types and delivery routes
>> Mechanisms and drug targets
This webinar is the essential pharma R&D trend and forecast overview you need to be positioned for success in 2016.
Watch the full webinar here http://ow.ly/4mOGmk
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Background: The efficacy and safety of 6-mercaptopurine (6-MP) therapy rely on the concentration of its metabolites. The aim of the current study is the pharmacokinetic analysis of 6-MP and the detection of its metabolites as well as the role of Thiopurine S-methyl transferase (TPMT), the enzyme associated with 6-MP metabolism, as a pharmacogenomics biomarker.
Alexander Börve of Gothenburg University and iDoc24, reviews an innovative mHealth app that confidentially connects user to clinician to review STD exposure and symptoms. Presented at YTH Live 2014 session "Advances in STD Diagnosis and Results."
An evaluation of community pharmacists’ readiness to implement the Falsified ...RavinaBarrett
Pharmacies are not FMD compliant and limited practical help and support seems available. A lack of resources, knowledge, competency, training and confidence makes this a difficult directive to implement successfully. Improved patient safety is anticipated, but difficult to quantify.
Neglected and rare diseases traditionally have not been the focus of large pharmaceutical company research as biotech and academia have primarily been involved in drug discovery efforts for such diseases. This area certainly represents a new opportunity as the pharmaceutical industry investigates new markets. One approach to speed up drug discovery is to examine new uses for existing approved drugs; this is termed drug repositioning or drug repurposing and has become increasingly popular in recent years. Analysis of the literature reveals that using high-throughput screening there have been many examples of FDA approved drugs found to be active against additional targets that can be used to therapeutic advantage for repositioning for other diseases. To date there are far fewer such examples where in silico approaches have allowed for the derivation of new uses. It is suggested that with current technologies and databases of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge. In this publication a review of the literature will highlight several proof of principle examples from areas such as finding new inhibitors for drug transporters with 3D pharmacophores and uncovering molecules active against Mycobacterium tuberculosis (Mtb) using Bayesian models of compound libraries. Research into neglected or rare/orphan diseases can likely benefit from in silico drug repositioning approaches and accelerate drug discovery for these diseases.
Dr. Eliana Paladino - How the GFI#213/VFD Affected the Pattern of Submissions...John Blue
How the GFI#213/VFD Affected the Pattern of Submissions at the UMN-VDL - Dr. Eliana Paladino, from the 2017 Allen D. Leman Swine Conference, September 16-19, 2017, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2017-leman-swine-conference-material
CONSISTENCY OF CLINICAL DATA REPORTING BETWEEN CLINICALTRIALS.GOV AND PUBLICA...Clarinda Cerejo
This poster presents a summary of research conducted to assess consistency of data reporting between clinical trials listed on clinicaltrials.gov and corresponding peer-reviewed medical publications for oncology drugs approved by the FDA between 2014 and 2016.
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
This slide deck was developed for a lecture at a conference on Drug Discovery and Development organized by the prestigious NIPER, Hyderabad in Mar 2017
Your fast-pass to the news, insights, and storylines you need to know.
Watch the full webinar here http://ow.ly/4mOGmk
Hosted by Master of Ceremonies Ian Lloyd, senior director of Pharmaprojects and data integration, this webinar spotlights the blockbuster trends and rising stars of global R&D 2016 as seen in this year’s Annual Review.
During this presentation, Ian Lloyd & Scrip Managing Editor, Alex Shimmings cover:
>> Year-on-year growth
>> Clinical phases trends
>> Top companies and the shape of the industry
>> Mergers and acquisitions
>> Trending therapies, diseases, drug types and delivery routes
>> Mechanisms and drug targets
This webinar is the essential pharma R&D trend and forecast overview you need to be positioned for success in 2016.
Watch the full webinar here http://ow.ly/4mOGmk
Weekly News Wrap-up on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news
Background: The efficacy and safety of 6-mercaptopurine (6-MP) therapy rely on the concentration of its metabolites. The aim of the current study is the pharmacokinetic analysis of 6-MP and the detection of its metabolites as well as the role of Thiopurine S-methyl transferase (TPMT), the enzyme associated with 6-MP metabolism, as a pharmacogenomics biomarker.
Alexander Börve of Gothenburg University and iDoc24, reviews an innovative mHealth app that confidentially connects user to clinician to review STD exposure and symptoms. Presented at YTH Live 2014 session "Advances in STD Diagnosis and Results."
An evaluation of community pharmacists’ readiness to implement the Falsified ...RavinaBarrett
Pharmacies are not FMD compliant and limited practical help and support seems available. A lack of resources, knowledge, competency, training and confidence makes this a difficult directive to implement successfully. Improved patient safety is anticipated, but difficult to quantify.
Neglected and rare diseases traditionally have not been the focus of large pharmaceutical company research as biotech and academia have primarily been involved in drug discovery efforts for such diseases. This area certainly represents a new opportunity as the pharmaceutical industry investigates new markets. One approach to speed up drug discovery is to examine new uses for existing approved drugs; this is termed drug repositioning or drug repurposing and has become increasingly popular in recent years. Analysis of the literature reveals that using high-throughput screening there have been many examples of FDA approved drugs found to be active against additional targets that can be used to therapeutic advantage for repositioning for other diseases. To date there are far fewer such examples where in silico approaches have allowed for the derivation of new uses. It is suggested that with current technologies and databases of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge. In this publication a review of the literature will highlight several proof of principle examples from areas such as finding new inhibitors for drug transporters with 3D pharmacophores and uncovering molecules active against Mycobacterium tuberculosis (Mtb) using Bayesian models of compound libraries. Research into neglected or rare/orphan diseases can likely benefit from in silico drug repositioning approaches and accelerate drug discovery for these diseases.
Dr. Eliana Paladino - How the GFI#213/VFD Affected the Pattern of Submissions...John Blue
How the GFI#213/VFD Affected the Pattern of Submissions at the UMN-VDL - Dr. Eliana Paladino, from the 2017 Allen D. Leman Swine Conference, September 16-19, 2017, St. Paul, Minnesota, USA.
More presentations at http://www.swinecast.com/2017-leman-swine-conference-material
CONSISTENCY OF CLINICAL DATA REPORTING BETWEEN CLINICALTRIALS.GOV AND PUBLICA...Clarinda Cerejo
This poster presents a summary of research conducted to assess consistency of data reporting between clinical trials listed on clinicaltrials.gov and corresponding peer-reviewed medical publications for oncology drugs approved by the FDA between 2014 and 2016.
The value of early asset development and commercializationCello Health
Worldwide pharmaceutical R&D spend is increasing each year, and the competition for a share of that investment is becoming fiercer. Companies need to demonstrate the potential value of their asset in commercial as well as scientific and clinical terms.
The slides in this deck define and identify value from a financial, clinical and commercial perspective while also exploring how to derive value for patients.
This slide deck was developed for a lecture at a conference on Drug Discovery and Development organized by the prestigious NIPER, Hyderabad in Mar 2017
Uveitis global clinical trials review, h1, 2015Ambikabasa
Product Synopsis
Uveitis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, Uveitis Global Clinical Trials Review, H1, 2015" provides an overview of Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database.
http://www.researchmoz.us/uveitis-global-clinical-trials-review-h1-2015-report.html
Evaluation of pregnancy outcomes after thyroid surgeryAI Publications
Background: According to contemporary cancer data, women account for roughly 75% of differentiated thyroid carcinoma (DTC), with the largest incidence occurring in individuals aged 50-59 years in the United States. Objective: This paper aims to evaluate of pregnancy outcomes after thyroid surgery. Patients and methods: This paper was interested to analyse and evaluate of pregnancy outcomes after thyroid surgery by radioactive iodine therapy, which includes 42 cases of pregnant women which suffered of thyroid and processes of thyroid surgery were applied in different hospitals in Iraq from 15th March 2021 to 27th July 2022. This data collected were analysed and conducted all demographic characteristics by the SPSS program. Discussion: This paper was presented different outcomes of pregnant women patients where it presented that the women have overweight were more struggled than those underweight due to a goiter which causes an overweight. In addition, the outcomes of pregnancy outcomes after surgery were got low birth weight; baby were most of the risk factors that have a high influenced on the women after pregnancy, with where it covered 7.1% of women. Furthermore, in the evaluations of blood pressure measurements post-operative of pregnant women surgery where this study diastolic blood pressure of women measurements after surgery and during surgery which found 57.14% for women have a blood pressure of <80 mm Hg and 23.81 for women have 80-89 mm Hg as well as 19.05 for women have >90 mm Hg. Conclusion: In conclusion, this study indicates that there is uncontrolled hyperthyroidism in pregnant patients, which causes many effects. In addition, this study showed that thyroidectomy surgery was successful, but our study found that there is an increased risk in the case of premature delivery before radioactive iodine treatment. After thyroid surgery, radioactive iodine therapy may be required in some thyroid cancer instances. As of currently, this paper suggests women waiting at least six months before getting pregnant after receiving radioactive iodine therapy due to worries about potential radiation impacts on the unborn child's development.
Jean Pierre Paccioni, EIPG President
Presentation at EIPG – BIPA Symposium “Clinical Trials Research” at the Faculty of Pharmacy, Medical University of Sofia, Sofia 2014.
Post-Approval Studies are an Essential Phase of Drug Development with Important Implications for Life Science Companies. observed in clinical trials creating treatment and safety gaps, which can undermine return on investment for all healthcare stakeholders.
Presentation from the 3rd Joint Meeting of the Antimicrobial Resistance and Healthcare-Associated Infections (ARHAI) Networks, organised by the European Centre of Disease Prevention and Control - Stockholm, 11-13 February 2015
INTRODUCTION: This research aims at enlightens and emphasizing the most prevailing disease conditions and disorders which are most common in mahabubnagar locality ,were category A(augmented) type ADR are more followed by type C(continous).
METHODS: A retrospective research study was conducted using Naronji's and WHO standard scales have been used to categorise the ADR into category A, category B, category C and category D for the given cases.
Epidemological data like age, ADR, and disease condition prevailing in hospitalised patients are noted and categorised department wise.
Australia Lung Cancer Drugs Market Analysis Sample ReportInsights10
Lung cancer is the fifth most common type of cancer affecting the Australian population, therefore the Australian lung cancer drugs market is projected to grow during the forecast period. The market is segmented by type, treatment, end user, route of administration, and distribution channel. To get a detailed report, contact us at - info@insights10.com
SVMPharma Real World Evidence – Real World Evidence as a driver of HTA approv...SVMPharma Limited
SVMPharma Real World Evidence (RWE) – In this article we examine the benefits of RWE in support of HTA submissions and re-submissions, and ask whether RWE is something you can afford to pass up. For more resources RWE visit us at svmpharma.com
Chronic Cough Market 2023: Epidemiology, Industry Trends, Size, Share And For...frankmorgan27
The growing cases of respiratory infections owing to high levels of air pollution, prolonged exposure to dust and chemical fumes, chain smoking, etc., are primarily driving the chronic cough market.
Slides from the presentation on extrapolation from progression free survival to overall survival in oncology given at the 2017 HTAi Annual Meeting in Rome
Similar to Clinical trials industry strategies (20)
TOP AND BEST GLUTE BUILDER A 606 | Fitking FitnessFitking Fitness
"Feature:
• Intelligent Ergonomically Design Glute Builder Is A Must Have For Those Looking To Target Their Gluteal Muscles And Hamstrings With Precision.
• The Ability To Adjust The Starting Position, This Machine Allows For A More Targeted Workout That Is Tailored To Your Specific Needs.
• Spacious And Supportive Cushioned Seat Provide Added Comfort And Stability During Your Workout."
Get more information visit on:- www.fitking.in
Our mail I.D:-care@fitking.in, fitking.in@gmail.com
Call us at :- 9958880790, 9870336406, 8800695917
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Letter to MREC - application to conduct studyAzreen Aj
Application to conduct study on research title 'Awareness and knowledge of oral cancer and precancer among dental outpatient in Klinik Pergigian Merlimau, Melaka'
KEY Points of Leicester travel clinic In London doc.docxNX Healthcare
In order to protect visitors' safety and wellbeing, Travel Clinic Leicester offers a wide range of travel-related health treatments, including individualized counseling and vaccines. Our team of medical experts specializes in getting people ready for international travel, with a particular emphasis on vaccines and health consultations to prevent travel-related illnesses. We provide a range of travel-related services, such as health concerns unique to a trip, prevention of malaria, and travel-related medical supplies. Our clinic is dedicated to providing top-notch care, keeping abreast of the most recent recommendations for vaccinations and travel health precautions. The goal of Travel Clinic Leicester is to keep you safe and well-rested no matter what kind of travel you choose—business, pleasure, or adventure.
The global radiation oncology market size reached US$ 8.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 14.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/radiation-oncology-market
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden